Obesity and Weight Management Market Campaigns, Clinical Differentiation, and Access Expansion in Q4 2025 

Companies in the obesity and weight management market prioritized integrated strategies that combined campaigns, robust clinical evidence, and expanded affordability programs to enhance engagement and access. Currax advanced the “Real Patients, Real Results” campaign for Contrave, while Lilly strengthened Mounjaro and Zepbound through provider education, digital adherence tools, and branded initiatives supported stigma awareness, affordability, and broader patient access. Novo Nordisk reinforced a new dose formulation, regulatory submissions, and study data for Wegovy. Vivus enhanced Qsymia’s value proposition through nationwide price reductions, Rhythm progressed Imcivree with regulatory and reimbursement gains, and Lilly advanced orforglipron with positive Phase 3 results, significant manufacturing investment, and federal access initiatives.